@Reuters: Sanofi MS drug tolebrutinib misses goal in relapsing disease trials

Sanofi MS drug tolebrutinib misses goal in relapsing disease trials https://t.co/N259JhOoGf pic.twitter.com/X2AQ8atT2j

— Reuters (@Reuters) September 2, 2024